How This Evidence Evolved
Testicular Cancer Surveillance
Surveillance and risk-adapted treatment after orchiectomy
Timeline
Early observations and pilot data that first suggested a new direction
Landmark RCTs and pivotal trials that established the evidence base
Relapse-free rate at 2 years: radiotherapy 96.7% vs carboplatin 97.7%; at 3 years 95.9% vs 94.8% (HR 1.28, 90% CI 0.85-1.93, p=0.32)
Relapse at median 6.3 years: 28% overall; high-risk 49.2% vs low-risk 14.2% in the 1993-2005 cohort (p<0.0001); 5-year disease-specific survival 98.9-99.3%
Relapse-free rate at 5 years: 82.3% overall; tumor ≤4 cm vs >4 cm 87% vs 76% (P=.003); multivariate HR 2.0 (95% CI 1.3-3.2) for size >4 cm and 1.7 (1.1-2.6) for rete testis invasion
Relapse at median 11.3 years: 27/105 (25.7%); disease deaths 3/105 (2.8%)
Follow-up studies, subgroup analyses, and real-world validation
Relapse-free survival and cancer-specific survival
Six-year stage ≥IIC relapse incidence: MRI vs CT and three vs seven scans
Current standard of care and ongoing research directions
Landmark Trials in This Story
Randomized trial of two or five computed tomography scans in the surveillance of patients with stage I nonseminomatous germ cell tumors of the testis: Medical Research Council Trial TE08, ISRCTN56475197--the National Cancer Research Institute Testis Cancer Clinical Studies Group.
Intermediate- or poor-prognosis relapse at median 40 months: two CT scans (3, 12 months) 0.8% vs five 0.6% (difference 0.2%, 90% CI -1.2% to 1.6%)
Radiotherapy versus single-dose carboplatin in adjuvant treatment of stage I seminoma: a randomised trial.
Relapse-free rate at 2 years: radiotherapy 96.7% vs carboplatin 97.7%; at 3 years 95.9% vs 94.8% (HR 1.28, 90% CI 0.85-1.93, p=0.32)
Non-risk-adapted surveillance in clinical stage I nonseminomatous germ cell tumors: the Princess Margaret Hospital's experience.
Relapse at median 6.3 years: 28% overall; high-risk 49.2% vs low-risk 14.2% in the 1993-2005 cohort (p<0.0001); 5-year disease-specific survival 98.9-99.3%
Prognostic factors for relapse in stage I seminoma managed by surveillance: a pooled analysis.
Relapse-free rate at 5 years: 82.3% overall; tumor ≤4 cm vs >4 cm 87% vs 76% (P=.003); multivariate HR 2.0 (95% CI 1.3-3.2) for size >4 cm and 1.7 (1.1-2.6) for rete testis invasion
Clinical stage I testis cancer: long-term outcome of patients on surveillance.
Relapse at median 11.3 years: 27/105 (25.7%); disease deaths 3/105 (2.8%)
One course of adjuvant BEP in clinical stage I nonseminoma mature and expanded results from the SWENOTECA group
Relapse-free survival and cancer-specific survival
Imaging Modality and Frequency in Surveillance of Stage I Seminoma Testicular Cancer: Results From a Randomized, Phase III, Noninferiority Trial (TRISST)
Six-year stage ≥IIC relapse incidence: MRI vs CT and three vs seven scans
Serum Levels of MicroRNA-371a-3p (M371 Test) as a New Biomarker of Testicular Germ Cell Tumors: Results of a Prospective Multicentric Study.
Primary GCT diagnosis: sensitivity 90.1%, specificity 94.0%, ROC AUC 0.966. Teratoma did not express the marker. Relapse levels normalized upon remission; further validation required before clinical implementation.
Explore the evidence yourself
Ask AttendMe about any trial, guideline, or clinical question. Evidence-ranked answers from 3.7M+ peer-reviewed articles.